Ratnakar Securities Pvt. Ltd.

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC

BSE5176.30-28.4 (-0.55 %)

PREV CLOSE ( ) 5204.70

OPEN PRICE ( ) 5000.05

BID PRICE (QTY) 5168.25 (1)

OFFER PRICE (QTY) 5186.45 (4)

VOLUME 382

TODAY'S LOW / HIGH ( )5000.05 5188.50

52 WK LOW / HIGH ( )3102 7208

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 11-07 1979

Management Info

Narayan K Seshadri - Chairman Sanjeev Kumar Panchal - Managing Director

Registered Office

Address Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring Road,
Bengaluru,
Karnataka-560045

Phone 080 6774 8000

Email comp.secy@astrazeneca.com

Website www.astrazenecaindia.com/india

Registrars Details

Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)

30, Ramana Residency,4th Cross, Sampige Road,Malleswaram,Bangalore

Listing : BSE, NSE, MCX

NEWS

27Mar AstraZeneca Pharma gets nod to import
AstraZeneca Pharma India has received permission to import for sale and..

27Mar AstraZeneca Pharma surges on getting n
Astrazeneca Pharma India is currently trading at Rs. 5258.00, up by 198...

11Mar AstraZeneca Pharma India, Mankind Phar
AstraZeneca Pharma India and Mankind Pharma have entered into an agreeme..

11Mar Astrazeneca Pharma India informs about
Astrazeneca Pharma India has enclosed copy of press release in connectio..

20Feb AstraZeneca Pharma India informs about
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..

Financials

in Millions

	QTR Dec 23	ANNUAL 23
Net Profit	158	992.929999999999
Gross Profit	203.98	1341.05
Operating Profit	247.16	1914.27
Net Sales	3057.89	10029.71

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Solara Active Pharma (BSE) 526.95 (11.15%)	M.Cap ( in Cr)1672.03
NGL Fine-Chem (BSE) 2584.95 (1.67%)	M.Cap ( in Cr)1547.32
Concord Biotech (BSE) 1601.15 (1.43%)	M.Cap ( in Cr)16445.14
Wockhardt (BSE) 588.60 (2.62%)	M.Cap ( in Cr)8937.14
Windlas Biotech (BSE) 532.85 (2.69%)	M.Cap ( in Cr)1081.63

Shareholding Pattern

	PROMOTERS	75%
	MUTUAL FUNDS/UTI	3.75%
	NON-INSTITUTION	18.49%
	FI/BANKS/INSURANCE	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Quant Healthcare Fu...	2.34
ICICI Pru Pharma He...	1.61
ICICI Pru Innovatio...	0.93
Nippon India Small ...	0.76
Nippon India Pharma...	0.48
Motilal Oswal S&P B...	0.33

attention investors
kyc
ipo
ibt trading

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

ASTRAZENECA PHARMA INDIA LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES